aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-21 15:30Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the drug Efzofitimod, which led to significant financial losses for investors [1][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1]. Allegations Against aTyr - The complaint alleges that aTyr and its executives made false and misleading statements about the efficacy of Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [3]. - The company is accused of providing overly positive statements while concealing material adverse facts, which resulted in shareholders purchasing securities at artificially inflated prices [3]. Clinical Study Results - In the EFZO-FIT study, efzofitimod did not show a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [4]. - Following the release of these results, aTyr's stock price plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [4].